{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:11Z","timestamp":1794277211592,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T22:25:19Z","timestamp":1786141519000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FR\u03b1), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes"],"prefix":"10.1016","volume":"212","author":[{"given":"Orazio","family":"De Tommasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ottum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias M.P.","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.002_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-pathol-020117-043609","article-title":"Molecular genetics of endometrial carcinoma","volume":"14","author":"Bell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0010","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/ijgc-2024-005607","article-title":"The clinical landscape of antibody-drug conjugates in endometrial cancer","volume":"34","author":"Fuc\u00e0","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2006.10.063","article-title":"Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma","volume":"105","author":"Dainty","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2025.04.590","article-title":"TROP2 expression and therapeutic targeting in uterine carcinosarcoma","volume":"197","author":"Moufarrij","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0055","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/j.ygyno.2026.01.667","article-title":"Remarkable preclinical activity of Trastuzumab-Deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts","volume":"208","author":"Palmieri","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0060","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6890-12-22","article-title":"Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma","volume":"12","author":"Bignotti","year":"2012","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.25891","article-title":"Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","volume":"117","author":"Varughese","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0085","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0090","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2025.05.001","article-title":"FR\u03b1 expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates","volume":"197","author":"Xiao","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2023.12.017","article-title":"A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR\u03b1-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer","volume":"182","author":"Cristea","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-71102-x","article-title":"Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial","volume":"17","author":"Porter","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s44276-025-00125-6","article-title":"HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups","volume":"3","author":"Aro","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0120","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.5858\/arpa.2025-0046-RA","article-title":"The rapidly evolving landscape of human epidermal growth factor receptor 2 (HER2) testing in endometrial carcinoma and other gynecologic malignancies","volume":"150","author":"Buza","year":"2025","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0125","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2026.37.e86","article-title":"Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low","volume":"37","author":"Yoon","year":"2026","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2531105123","article-title":"Integrated mutational landscape analysis of endometrial stromal sarcoma","volume":"123","author":"Hartwich","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0144","article-title":"A phase II evaluation of the efficacy and safety of sacituzumab govitecan in patients with recurrent uterine cancer","author":"Santin","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0150","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0155","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/jcm13082158","article-title":"The expression and amplification of HER2 has a significant impact on the prognosis of endometrial carcinoma in Korean patients","volume":"13","author":"Kim","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0160","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","article-title":"Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody","volume":"21","author":"Bignotti","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15533","article-title":"Folate receptor alpha (FR\u03b1 \/ FOLR1) and HER2 immunohistochemical staining in high-grade endometrial carcinoma with aberrant p53 expression","volume":"88","author":"McHenry","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5603\/gpl.96605","article-title":"Expression of B7-H4 in endometrial cancer and its impact on patients\u2019 prognosis","volume":"95","author":"Gorzelnik","year":"2024","journal-title":"Ginekol. Pol."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-025-04227-8","article-title":"Exploring Nectin-4 as a potential diagnostic biomarker in endometrial adenocarcinoma: title page","volume":"26","author":"Ordu","year":"2025","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ygyno.2026.08.002_bb0180","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Rep."},{"key":"10.1016\/j.ygyno.2026.08.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag053","article-title":"Prognostic and histologic significances of the expression profile of membrane tissue factor for aggressive endometrial carcinomas","volume":"31","author":"Fujieda","year":"2026","journal-title":"Oncologist"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:42:59Z","timestamp":1789692179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0090825826020925"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FR\u03b1), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}